Memorial Sloan Kettering Cancer Center has been granted a patent for chimeric Newcastle disease viruses that include a transgene encoding interleukin-12. These viruses are designed for cancer treatment in combination with PD-1 antagonists or ligands, enhancing therapeutic efficacy. GlobalData’s report on Memorial Sloan Kettering Cancer Center gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Memorial Sloan Kettering Cancer Center, was a key innovation area identified from patents. Memorial Sloan Kettering Cancer Center's grant share as of June 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Chimeric newcastle disease virus for cancer treatment
The granted patent US12042534B2 describes a chimeric Newcastle disease virus (NDV) that incorporates a transgene encoding human interleukin-12 (IL-12). The claims specify that the packaged genome of the chimeric NDV includes the negative sense RNA sequence corresponding to specific nucleotide sequences (SEQ ID NO:61 or 26) and the amino acid sequences of IL-12 (SEQ ID NO:43 or 42). Additionally, the patent outlines variations of the chimeric NDV, including those with a LaSota strain backbone and a mutated F protein with a specific amino acid mutation (L289A). The transgene can be strategically inserted between the NDV P gene and the NDV M gene within the genome.
Furthermore, the patent claims the inclusion of various transcription units for NDV genes (NP, P, M, F, HN, and L) in the packaged genome. Specific nucleotide sequences (SEQ ID NO:51, 52, or 60) are also referenced for the genome's composition. The patent extends to pharmaceutical compositions that comprise the chimeric NDV in combination with a pharmaceutically acceptable carrier, indicating potential applications in therapeutic contexts. This innovative approach may enhance the utility of NDV as a vector for delivering therapeutic agents, particularly in immunotherapy targeting human diseases.
To know more about GlobalData’s detailed insights on Memorial Sloan Kettering Cancer Center, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
